spacer
home > ebr > autumn 2017 > adapt to survive
PUBLICATIONS
European Biopharmaceutical Review

Adapt to Survive

No market is immune to change, and life sciences continues to face its fair share of upheaval as the industry accommodates emerging innovation in healthcare and a raft of other challenges to the status quo. Below are five of the most prominent trends and what they mean in practice.

Strategic Acquisitions

As a shortcut to attractive new product lines, when development and testing cycles can be frustratingly long, companies are increasingly sizing up strategic purchases. 2016 saw high levels of merger and acquisition (M&A) activity and more of the same had been forecast for 2017 (1,2). Though this has not quite materialised so far, it is expected to pick up in the second half of the year.

However, profiting from these deals means the acquiring company must be able to align its branding, content and labelling quickly, reliably and efficiently. This is essential in upholding brand image, stabilising compliance efforts and maximising process efficiency, as well as market opportunity.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
1
     

There are no comments in regards to this article.

spacer
Peter Muller is Managing Director for Schlafender Hase, Americas. For the last 20 years, he has worked on software and process improvement projects with Fortune 500 companies from various industries including pharma, consumer goods, food, aerospace and defence. Peter has a wealth of experience working with international clients to define their organisations’ goals and help them leverage new technologies to achieve productivity gains, process improvements and cost savings.
spacer
Peter Muller
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta and Cytiva collaborating on COVID-19 rapid test

Cambridge and Wetherby, UK, 08 April 2020: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Cytiva, formerly known as GE Healthcare Life Sciences. The companies will develop and manufacture an Affimer-based point-of-care rapid test intended for screening of large populations to diagnose the COVID-19 coronavirus infection.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement